Today: 7 February 2026
Subscribe
Browse Category

SHA:688396 News 18 January 2026 - 2 February 2026

China Resources Microelectronics (688396) stock slides as filing flags 2026 price rises, SiC push

China Resources Microelectronics (688396) stock slides as filing flags 2026 price rises, SiC push

China Resources Microelectronics’ Class A shares fell 3.6% to 61.50 yuan in Shanghai by 0953 GMT+8, underperforming the SSE Composite Index, which slipped 0.7%. Rival chipmakers Montage Technology and GigaDevice Semiconductor gained 2% and 7%. Investors await the company’s April 25 earnings report for evidence that recent price hikes and product upgrades are improving margins.
2 February 2026
···
China Resources Microelectronics stock price in focus: filing flags 2026 revenue lift, higher margins and SiC push

China Resources Microelectronics stock price in focus: filing flags 2026 revenue lift, higher margins and SiC push

China Resources Microelectronics shares closed at 63.77 yuan in Shanghai, down 0.02% after trading between 61.50 and 64.65. The chipmaker forecast “positive” revenue and margin growth for 2026, citing demand in autos, energy storage, and AI. Management highlighted plans to expand 12-inch wafer capacity and boost third-generation semiconductor output. Shares have risen about 20.6% since January 1.
1 February 2026
···
China Resources Microelectronics (688396) stock jumps 13% near 52-week high as China chip trade heats up

China Resources Microelectronics (688396) stock jumps 13% near 52-week high as China chip trade heats up

China Resources Microelectronics A-shares closed up 13.04% at 68.20 yuan in Shanghai Friday, with 58.24 million shares traded and turnover of 3.79 billion yuan. The surge followed shareholder approval of a 2026 related-party transaction plan and changes to governance rules. A storage-chip index hit a record high, while DRAM and NAND prices are forecast to jump sharply in Q1 2026.
18 January 2026
···

Stock Market Today

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

7 February 2026
Bank of America shares rose 2.89% Friday to $56.53, tracking a rally in U.S. financial stocks as the Dow closed above 50,000. The bank will redeem its Series DD preferred stock and related depositary shares on March 10 at $1,000 per share. CEO Brian Moynihan donated 100,000 shares on Feb. 4, a regulatory filing showed. Key U.S. jobs and inflation data are due next week after delays.
Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

7 February 2026
Oracle shares jumped 4.65% to $142.82 Friday, ending an eight-day slide but remaining down 22% since Jan. 27. The company has set up a $20 billion at-the-market stock program and completed a $25 billion senior notes sale to fund cloud expansion. Oracle’s liabilities stood at $174.5 billion as of Nov. 30, 2025, before the new financing. Investors remain focused on dilution risks and the pace of capacity growth.
Go toTop